Hympavzi has been given a list price of $795,600 per year before discounts and rebates, which Pfizer said was in line with other prophylactic treatments for haemophilia A or B currently available ...

Hympavzi's closest counterpart in the TFPI category is Novo Nordisk's concizumab, which was turned down by the FDA last year due to manufacturing issues.

本周新药行情回顾： 2025年6月30日-2025年7月4日，新药板块涨幅前5企业：神州细胞(45.00%)、圣诺医药(36.30%)、前沿生物(30.60%)、微芯生物(30.50%)、康方生物(25.50%)；跌幅前5企业：欧康维视(-12.90%)、科济药业(-9.10%)、东曜药业(-6.70%)、乐普生物(-6.40%)、益方生物(-3.60%)。 本周新药行业重点分析： 本周，国家医保 ...

FDA officials issued the import alerts Tuesday to prevent 58 models of Olympus devices used in urinary, respiratory, abdominal and pelvic procedures from reaching customers in the U.S.

Merck & Co., Inc. (NYSE:MRK) ranks among the best set-it-and-forget-it stocks to buy. On June 27, TD Cowen maintained its Hold rating and $100 price target on Merck & Co., Inc. (NYSE:MRK) after a vote ...

Below are the ratings of the most accurate analysts for three high-yielding stocks in the health care sector. TaxStatus is the only firm to provide the comprehensive information advisors need to ...